A monthly roundup of key articles in other journals

In this report, Chao et al. explored the dynamics of platelet activation in patients with COVID-19, across a four-week period encompassing acute illness and convalescence. Most patients (75.4%) received two transfusions;15.1% patients received one;and 9.5% received three. I High-titer convalescent plasma did not reduce death or progression to severe respiratory failure in patients hospitalized with COVID-19 in the i " I Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 [TSUNAMI] i " I trial i . [Extracted from the article] Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

A monthly roundup of key articles in other journals

B I Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Convalescent plasma (CP) for COVID-19 respiratory illness (CONCOR-1) - a multicenter, international, open-label, randomized controlled trial - evaluated the effectiveness of CP in patients hospitalized with COVID-19. While CP transfusion has failed to demonstrate efficacy in large randomized clinical trials of hospitalized patients, smaller studies suggest some efficacy in older patients if administered soon after symptom onset. [Extracted from the article] Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

A monthly roundup of key articles in other journals

Overall, this study suggests that thrombocytopenia was uncommon in patients with CVST prior to the pandemic and prevalence of anti-PF4 antibodies was very rare, consistent with vaccine-induced thrombotic thrombocytopenia being a new phenomenon. Very few patients were tested for anti-PF4 antibodies, and only one patient from the full cohort was definitively diagnosed with HIT (0.1%;95%CI, <0.1%-0.7%). Sánchez van Kammen M, Heldner MR, Brodard J, et al., JAMA 2021;326(4):332-338 i b I Thrombocytopenia and platelet factor 4 (PF4)/heparin antibodies were uncommon in patients presenting with cerebral venous sinus thrombosis (CVST) prior to the COVID-19 pandemic i . [Extracted from the article] Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A monthly roundup of key articles in other journals

Steady-state SCD patients showed elevated levels of all three types of RCDPs compared with healthy controls, while SCD patients experiencing a crisis had significantly higher levels of RCDPs and membrane fragments compared with controls. B I Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Hospitalized patients were assigned to receive therapeutic anticoagulation (20 mg rivaroxaban once daily for stable patients;enoxaparin 1 mg/kg twice daily for unstable patients following by rivaroxaban for 30 days [ I n i = 311]) or prophylactic anticoagulation (standard venous thromboembolism prophylaxis with unfractionated heparin or enoxaparin [ I n i = 304]). [Extracted from the article] Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)